Dark

Check out our Level2View

ARAV
Aravive, Inc. Common Stock
stock NASDAQ

Inactive

Jan 26, 2024

0.0401USD-13.391%(-0.0062)4,040,076

Pre-market

0.00USD-100.000%(-0.05)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

07:04AM EST Aravive Announces First Patient Dosed In Phase 2 Study Of Batiraxcept In Clear Cell Renal Cell Carcinoma Benzinga

07:00AM EST Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has dosed the first patient in the Phase 2 portion of the Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC). GlobeNewswire Inc

Jan 5, 2022

04:24PM EST Aravive S-3 Shows Registration For ~4.5M Share Common Stock Offering Via Selling Shareholders Benzinga

Jan 4, 2022

08:11AM EST The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives Benzinga

Jan 3, 2022

06:15PM EST Aravive Announces $10.0 Million Investment by Eshelman Ventures, GlobeNewswire Inc

Nov 15, 2021

07:00AM EST Aravive to Participate in Fireside Chat at Piper Sandler 33rd GlobeNewswire Inc

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:16AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:15AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:14AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:00AM EST 7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor decrease from baselineBatiraxcept has been well-tolerated with no dose-limiting toxicitiesConference call and webcast today at 8:30 a.m. ET GlobeNewswire Inc

Nov 9, 2021

11:41AM EST Aravive Announces Preliminary Data From Phase 1b Trial Evaluating Batiraxcept In Combination With Cabozantinib In Clear Cell Renal Cell Carcinoma To Be Presented At 2021 Society For Immunotherapy Of Cancer Annual Meeting Benzinga

08:00AM EST 3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data GlobeNewswire Inc

Oct 28, 2021

04:16PM EDT Aravive Q3 EPS $(0.53) Up From $(0.66) YoY Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

08:07AM EDT Aravive To Present New Preliminary Data From Phase 1b Trial Evaluating AVB-500 In Clear Cell Renal Cell Carcinoma At 2021 Society For Immunotherapy Of Cancer Annual Meeting Nov. 13 Benzinga

08:00AM EDT Aravive to Present New Preliminary Data from Phase 1b Trial GlobeNewswire Inc

Sep 16, 2021

07:00AM EDT Aravive to Participate in Fireside Chat at Cantor Fitzgerald GlobeNewswire Inc

Sep 1, 2021

07:00AM EDT Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 9, 2021

07:14AM EDT Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma Benzinga

07:00AM EDT Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel GlobeNewswire Inc

Aug 5, 2021

07:40AM EDT Aravive Q2 EPS $(0.35) Down From $(0.32) YoY Benzinga

07:01AM EDT Aravive Reports Second Quarter 2021 Financial Results and Provides GlobeNewswire Inc

Jul 30, 2021

01:40PM EDT Aravive-Sponsored Study Titled 'Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma' Posted To ClinicalTrials.Gov Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 15, 2021

07:00AM EDT Aravive Achieves Second Development Milestone from 3D Medicines GlobeNewswire Inc

Jul 7, 2021

07:00AM EDT Aravive to Participate in Fireside Chat at 2021 William Blair GlobeNewswire Inc

Jun 24, 2021

10:47AM EDT Aravive Up 8% After Reporting Positive Initial Results For RTTNews

10:21AM EDT Mid-Morning Market Update: Markets Open Higher; Accenture Reports Upbeat Q3 Results Benzinga

07:24AM EDT Aravive Says Positive Initial Results From Phase 1b Study Of AVB-500 With Cabozantinib In Clear Cell Renal Carcinoma RTTNews

07:07AM EDT Aravive Announces Initial Results From Phase 1b Portion Of Phase1b/2 Study Of AVB-500 In Combination With Cabozantinib In Clear Cell Renal Carcinoma; Says Was Well Tolerated And Co. Plans To Expand Dosing To Three Additional Patients Benzinga

07:00AM EDT Aravive Announces Positive Initial Results from Phase 1b Portion GlobeNewswire Inc

May 18, 2021

07:00AM EDT Aravive Announces Three New Appointments to its Board of Directors GlobeNewswire Inc

May 6, 2021

07:16AM EDT Aravive Q1 2021 Revs $256K; Q1 2021 EPS $(0.44) Vs $(0.72) YoY Benzinga

07:00AM EDT Aravive Reports First Quarter 2021 Financial Results and Announces GlobeNewswire Inc

Apr 27, 2021

07:06AM EDT Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer Benzinga

07:00AM EDT Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer GlobeNewswire Inc

Mar 19, 2021

07:46AM EDT The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs Benzinga

Mar 16, 2021

07:08AM EDT Aravive Q4 EPS $(0.25) Up From $(0.35) YoY Benzinga

07:00AM EDT Aravive Reports Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 12, 2021

07:01AM EST Aravive To Present Phase 1b Data Evaluating AVB-500 In Platinum Resistant Ovarian Cancer At 2021 Society Of Gynecologic Oncology Annual Meeting Mar. 19-25 Benzinga

07:00AM EST Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum GlobeNewswire Inc

Mar 8, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021 Benzinga

09:18AM EST BTIG Initiates Coverage On Aravive with Buy Rating, Announces Price Target of $26 Benzinga

07:11AM EST Aravive Doses First Patient Dosed In Phase 1b/2 Clinical Trial Of AVB-500 In Clear Cell Renal Cell Carcinoma RTTNews

07:08AM EST Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma Benzinga

07:00AM EST Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial GlobeNewswire Inc

Mar 2, 2021

07:00AM EST Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in March: GlobeNewswire Inc

Feb 16, 2021

07:16AM EST Aravive Announces $21M Registered Direct Offering Of 2.875M Shares At $7.29/Share Benzinga

07:00AM EST Aravive Announces $21.0 Million Registered Direct Offering with GlobeNewswire Inc

Jan 4, 2021

04:05PM EST Aravive, Inc.(Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics,today announced the Company will present at the H.C. Wainwright Virtual BioConnect Conference taking place January 11-14, 2021. Aravives presentation will be available for viewing on January 11, 2021. GlobeNewswire Inc

Dec 31, 2020

07:00PM EST Aravive, Inc.(Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics,today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective December 31, 2020. This transition will allow Dr. Tabibiazar to focus on a new venture. GlobeNewswire Inc

Nov 19, 2020

07:19AM EST Aravive Receives Guidance From FDA On Phase 3 Trial Design For AVB-500 RTTNews

07:00AM EST Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum GlobeNewswire Inc

Nov 16, 2020

04:05PM EST Aravive to Present at the Piper Sandler 32nd Annual Virtual GlobeNewswire Inc

Nov 10, 2020

04:05PM EST Aravive, Inc.(Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics,today announced the Company will host a virtual Ovarian and Renal Cancer Expert Event on Friday, November 20, 2020 from 9:00 a.m. to 10:30 a.m. ET. GlobeNewswire Inc

07:00AM EST Aravive to Receive $12 Million Signing Payment, up to an Additional $207Million in Future Milestone Payments plus Tiered Royalties GlobeNewswire Inc

Nov 5, 2020

05:05PM EST Aravive Q3 EPS $(1.69) Down From $(0.54) YoY Benzinga

Sep 18, 2020

07:46AM EDT William Blair Initiates Coverage On Aravive with Outperform Rating Benzinga

Sep 17, 2020

07:07AM EDT Aravive Appoints Michael Rogers To Board RTTNews

07:01AM EDT Aravive Appoints Michael W. Rogers to Board of Directors GlobeNewswire Inc

Sep 15, 2020

07:27AM EDT Aravive Appoints Reshma Rangwala As Chief Medical Officer RTTNews

07:11AM EDT Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer Benzinga

07:00AM EDT Aravive, Inc.(Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics,today announced the appointment of industry veteran and oncologist, Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer. GlobeNewswire Inc

Sep 8, 2020

07:00AM EDT Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in September: GlobeNewswire Inc

Aug 27, 2020

07:00AM EDT Aravive, Inc.(Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics,today announced the appointment of three industry veterans to its leadership team: Randy Anderson, Ph.D., Senior Vice President of Data Sciences, Elisabeth Gardiner, Ph.D., Vice President of Translational Medicine, and Patrick Simms, Vice President of Clinical Operations. GlobeNewswire Inc

Aug 3, 2020

04:09PM EDT Aravive Q2 EPS $(0.32) Down From $(0.27) YoY Benzinga

04:01PM EDT Aravive Reports Second Quarter 2020 Financial Results and Provides GlobeNewswire Inc

Jul 30, 2020

07:00AM EDT Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following three virtual investor conferences in August: GlobeNewswire Inc

Jul 23, 2020

12:18PM EDT HC Wainwright & Co. Maintains Buy on Aravive, Raises Price Target to $26 Benzinga

07:22AM EDT Aravive Reports Successful Completion Of Phase 1b Trial Evaluating AVB-500 In Platrinum-Resistant Ovarian Cancer Benzinga

07:00AM EDT Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500in Platinum Resistant Ovarian Cancer GlobeNewswire Inc

Share